Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Hepatology
•
Hepatology
What is your clinical approach to the evaluation of cytopenias in patients with end-stage liver disease?
Related Questions
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
When would you consider use of EUS guided liver biopsy over percutaneous and/or transjugular?
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
How do you incorporate palliative care specialists into the care of patients with chronic liver disease, especially those who may not be transplant candidates?
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
How do you approach the use of viscoelastic assays (ex: TEG, ROTEM) in patients with identified coagulopathy in the peri-procedural period?
How do you utilize Cystatin-C as a marker of renal dysfunction in patients with chronic liver disease?
What is your approach to a patient with "low" liver enzymes?
How do you decide whether ordering a 5' nucleotidase or a GGT is the most appropriate option in the evaluation of an elevated alkaline phosphatase?
